Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €4.43 EUR
Change Today -0.087 / -1.93%
Volume 106.7K
MDXH On Other Exchanges
EN Brussels
As of 11:35 AM 07/7/15 All times are local (Market data is delayed by at least 15 minutes).

mdxhealth (MDXH) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/24/15 - €5.88
52 Week Low
07/17/14 - €3.07
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for MDXHEALTH (MDXH)

Related News

No related news articles were found.

mdxhealth (MDXH) Related Businessweek News

No Related Businessweek News Found

mdxhealth (MDXH) Details

MDxHealth SA, a molecular diagnostics company, develops and commercializes epigenetic tests for cancer assessment, and the personalized treatment of patients. Its tests are based on proprietary gene methylation technology and assist physicians with the diagnosis of cancer, prognosis of recurrence risk, and prediction of response to a specific therapy. It focuses on providing molecular diagnostics products that address unmet clinical needs, as well as used in clinical laboratory testing. The company’s lead product is ConfirmMDx, which treats prostate cancer. Its product pipeline includes tests for bladder, kidney, and other urologic cancers. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA on October 2010. MDxHealth SA was founded in 2003 and is headquartered in Herstal, Belgium.

96 Employees
Last Reported Date: 05/1/15
Founded in 2003

mdxhealth (MDXH) Top Compensated Officers

Chief Executive Officer, President and Execut...
Total Annual Compensation: €491.1K
Compensation as of Fiscal Year 2014.

mdxhealth (MDXH) Key Developments

MDxHealth SA Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2015

MDxHealth SA reported unaudited earnings results for the first quarter ended March 31, 2015. Revenue was $4.0 million against $1.9 million last year. LBITDA was $2.6 million against $4.3 million last year. LBIT was $2.8 million against $4.3 million last year. Net loss was $2.5 million against $4.0 million last year.

MDxHealth SA Completes Enrollment of Second ConfirmMDx Clinical Utility Study

MDxHealth SA announced that it has completed patient enrollment into its prospective, randomized PASCUAL clinical utility study with ConfirmMDx® for Prostate Cancer. The study, which will evaluate the impact of the ConfirmMDx test results on physician decisions for repeat biopsy, enrolled 600 patients from 17 leading urology practices across the U.S. The ConfirmMDx for Prostate Cancer test, which helps urologists identify low risk men who may forego unnecessary repeat biopsy procedures, qualified for Medicare coverage on November 3, 2014. MDxHealth is conducting the PASCUAL study and enrolling providers into it's Certification and Training Registry as part of an ongoing commitment to ensure appropriate use of the ConfirmMDx test, in line with the LCD providing coverage of the test. If the interim analysis demonstrates a substantially lower repeat biopsy rate, Palmetto GBA will expand physician participation in the ConfirmMDx Registry, effectively increasing the number of Medicare patients covered. Unrestricted Medicare coverage, with the Registry requirement removed, is expected upon publication of favorable PASCUAL study results when the study is concluded.

MDxHealth SA Presents at BioCapital Europe 2015, Mar-26-2015 02:20 PM

MDxHealth SA Presents at BioCapital Europe 2015, Mar-26-2015 02:20 PM. Venue: Sofitel Legend Amsterdam, Amsterdam, Netherlands.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MDXH:BB €4.43 EUR -0.087

MDXH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bio-Reference Laboratories Inc $44.22 USD +0.76
Health Discovery Corp $0.03 USD -0.004
Imperial Innovations Group PLC 445.00 GBp -7.50
Miraculins Inc C$0.08 CAD -0.005
Vermillion Inc $1.95 USD -0.083
View Industry Companies

Industry Analysis


Industry Average

Valuation MDXH Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 15.1x
Price/Book 7.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 14.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MDXHEALTH, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at